{"id":"https://openalex.org/W1964705113","doi":"https://doi.org/10.1111/j.1460-9568.2005.04362.x","title":"Neuroprotective effects of metabotropic glutamate receptor ligands in a 6\u2010hydroxydopamine rodent model of Parkinson's disease","display_name":"Neuroprotective effects of metabotropic glutamate receptor ligands in a 6\u2010hydroxydopamine rodent model of Parkinson's disease","alternate_titles":[],"publication_year":2005,"publication_date":"2005-10-01","ids":{"openalex":"https://openalex.org/W1964705113","doi":"https://doi.org/10.1111/j.1460-9568.2005.04362.x","mag":"1964705113","pmid":"https://pubmed.ncbi.nlm.nih.gov/16197521"},"language":"en","primary_location":{"id":"doi:10.1111/j.1460-9568.2005.04362.x","doi":"https://doi.org/10.1111/j.1460-9568.2005.04362.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1460-9568.2005.04362.x","pdf_url":null,"source":{"id":"https://openalex.org/S171130801","display_name":"European Journal of Neuroscience","issn_l":"0953-816X","issn":["0953-816X","1460-9568"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Neuroscience","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1964705113"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058165911","display_name":"Anthony Christopher Vernon","orcid":"https://orcid.org/0000-0001-7305-1069","observed_orcids":["https://orcid.org/0000-0001-7305-1069"]},"institutions":[{"id":"https://openalex.org/I2802369498","display_name":"Charing Cross Hospital","ror":"https://ror.org/02gcp3110","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2802369498"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. C. Vernon","raw_affiliation_strings":["Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK","institution_ids":["https://openalex.org/I2802369498","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. Palmer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802369498","display_name":"Charing Cross Hospital","ror":"https://ror.org/02gcp3110","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2802369498"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Palmer","raw_affiliation_strings":["A.C.V. and S.P. contributed equally to this work","Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A.C.V. and S.P. contributed equally to this work","institution_ids":[]},{"raw_affiliation_string":"Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK","institution_ids":["https://openalex.org/I2802369498","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091653196","display_name":"Krishna P. Datla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802369498","display_name":"Charing Cross Hospital","ror":"https://ror.org/02gcp3110","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2802369498"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K. P. Datla","raw_affiliation_strings":["Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK","institution_ids":["https://openalex.org/I2802369498","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021903610","display_name":"Virginia Zbarsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802369498","display_name":"Charing Cross Hospital","ror":"https://ror.org/02gcp3110","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2802369498"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"V. Zbarsky","raw_affiliation_strings":["Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK","institution_ids":["https://openalex.org/I2802369498","https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086358165","display_name":"Martin J. Croucher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802369498","display_name":"Charing Cross Hospital","ror":"https://ror.org/02gcp3110","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2802369498"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. J. Croucher","raw_affiliation_strings":["Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK","institution_ids":["https://openalex.org/I2802369498","https://openalex.org/I47508984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034967345","display_name":"David Trevor Dexter","orcid":"https://orcid.org/0000-0002-7974-9588","observed_orcids":["https://orcid.org/0000-0002-7974-9588"]},"institutions":[{"id":"https://openalex.org/I2802369498","display_name":"Charing Cross Hospital","ror":"https://ror.org/02gcp3110","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300","https://openalex.org/I2802369498"]},{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"D. T. Dexter","raw_affiliation_strings":["Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parkinson's Disease Research Group, Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK","institution_ids":["https://openalex.org/I2802369498","https://openalex.org/I47508984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5034967345"],"corresponding_institution_ids":["https://openalex.org/I2802369498","https://openalex.org/I47508984"],"apc_list":{"value":3560,"currency":"USD","value_usd":3560},"apc_paid":null,"fwci":3.0367,"has_fulltext":false,"cited_by_count":82,"citation_normalized_percentile":{"value":0.90096878,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"22","issue":"7","first_page":"1799","last_page":"1806"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13991","display_name":"Nuclear Receptors and Signaling","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metabotropic-glutamate-receptors","display_name":"metabotropic glutamate receptors","score":0.9340000152587891},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.9300000071525574},{"id":"https://openalex.org/keywords/6-hydroxydopamine","display_name":"6-hydroxydopamine","score":0.9610000252723694},{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.9319999814033508},{"id":"https://openalex.org/keywords/excitotoxicity","display_name":"excitotoxicity","score":0.8450000286102295},{"id":"https://openalex.org/keywords/dopaminergic-neuron-degeneration","display_name":"dopaminergic neuron loss","score":0.8999999761581421},{"id":"https://openalex.org/keywords/substantia-nigra-pars-compacta","display_name":"substantia nigra pars compacta","score":0.9990000128746033},{"id":"https://openalex.org/keywords/striatum","display_name":"striatum","score":0.75},{"id":"https://openalex.org/keywords/mpep","display_name":"MPEP","score":0.8410000205039978},{"id":"https://openalex.org/keywords/ly367385","display_name":"LY367385","score":0.9890000224113464},{"id":"https://openalex.org/keywords/l-ap4","display_name":"L-AP4","score":0.9980000257492065},{"id":"https://openalex.org/keywords/tyrosine-hydroxylase","display_name":"tyrosine hydroxylase","score":0.8529999852180481}],"concepts":[{"id":"https://openalex.org/C2911016594","wikidata":"https://www.wikidata.org/wiki/Q15946111","display_name":"Hydroxydopamine","level":4,"score":0.811011552810669},{"id":"https://openalex.org/C25498285","wikidata":"https://www.wikidata.org/wiki/Q1981368","display_name":"Neuroprotection","level":2,"score":0.7864247560501099},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.7420299649238586},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.5612173676490784},{"id":"https://openalex.org/C49051014","wikidata":"https://www.wikidata.org/wiki/Q2033959","display_name":"Metabotropic glutamate receptor","level":4,"score":0.5235021710395813},{"id":"https://openalex.org/C41653306","wikidata":"https://www.wikidata.org/wiki/Q6589190","display_name":"Metabotropic glutamate receptor 5","level":5,"score":0.4789353311061859},{"id":"https://openalex.org/C61174792","wikidata":"https://www.wikidata.org/wiki/Q420510","display_name":"Glutamate receptor","level":3,"score":0.4359845519065857},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3549951910972595},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3394567370414734},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.33712148666381836},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.3060707449913025},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.28197968006134033},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20878860354423523}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001923","descriptor_name":"Brain Chemistry","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D003952","descriptor_name":"Diagnostic Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007150","descriptor_name":"Immunohistochemistry","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D007839","descriptor_name":"Functional Laterality","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D008024","descriptor_name":"Ligands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D013378","descriptor_name":"Substantia Nigra","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013378","descriptor_name":"Substantia Nigra","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013565","descriptor_name":"Sympatholytics","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D014446","descriptor_name":"Tyrosine 3-Monooxygenase","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016627","descriptor_name":"Oxidopamine","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D016923","descriptor_name":"Cell Death","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018094","descriptor_name":"Receptors, Metabotropic Glutamate","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D018691","descriptor_name":"Excitatory Amino Acid Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1460-9568.2005.04362.x","doi":"https://doi.org/10.1111/j.1460-9568.2005.04362.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1460-9568.2005.04362.x","pdf_url":null,"source":{"id":"https://openalex.org/S171130801","display_name":"European Journal of Neuroscience","issn_l":"0953-816X","issn":["0953-816X","1460-9568"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Neuroscience","raw_type":"journal-article"},{"id":"pmid:16197521","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16197521","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The European journal of neuroscience","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":44,"referenced_works":["https://openalex.org/W249845531","https://openalex.org/W1595002521","https://openalex.org/W1716703308","https://openalex.org/W1926939570","https://openalex.org/W1947356649","https://openalex.org/W1974366641","https://openalex.org/W1979480763","https://openalex.org/W1991542726","https://openalex.org/W1996942781","https://openalex.org/W1997243628","https://openalex.org/W1998656003","https://openalex.org/W2002574600","https://openalex.org/W2002613500","https://openalex.org/W2011434472","https://openalex.org/W2014439239","https://openalex.org/W2023478858","https://openalex.org/W2031125523","https://openalex.org/W2032122746","https://openalex.org/W2043473753","https://openalex.org/W2043859166","https://openalex.org/W2044896893","https://openalex.org/W2044956956","https://openalex.org/W2046592350","https://openalex.org/W2050903686","https://openalex.org/W2053544252","https://openalex.org/W2060714812","https://openalex.org/W2061934797","https://openalex.org/W2066961374","https://openalex.org/W2067795636","https://openalex.org/W2072926617","https://openalex.org/W2077326004","https://openalex.org/W2089721916","https://openalex.org/W2089873014","https://openalex.org/W2100519696","https://openalex.org/W2106042714","https://openalex.org/W2112972456","https://openalex.org/W2118900648","https://openalex.org/W2133829654","https://openalex.org/W2135342911","https://openalex.org/W2140142911","https://openalex.org/W2148790914","https://openalex.org/W2150012659","https://openalex.org/W2153450997","https://openalex.org/W4322703206"],"related_works":["https://openalex.org/W2499323677","https://openalex.org/W2049606977","https://openalex.org/W1986267411","https://openalex.org/W2496251418","https://openalex.org/W2053126592","https://openalex.org/W1986491834","https://openalex.org/W2795040646","https://openalex.org/W2285970859","https://openalex.org/W2371910871","https://openalex.org/W1547047969"],"abstract_inverted_index":{"Increasing":[0],"evidence":[1],"implicates":[2],"glutamate-mediated":[3],"excitotoxicity":[4,37],"as":[5],"a":[6,49,122],"contributory":[7],"factor":[8],"in":[9,13,20,38,63,76,128],"dopaminergic":[10],"cell":[11],"death":[12],"the":[14,41,44,65,92,103,111,138],"substantia":[15],"nigra":[16],"pars":[17],"compacta":[18],"(SNc)":[19],"Parkinson's":[21],"disease":[22],"(PD).":[23],"Previous":[24],"studies":[25],"have":[26],"suggested":[27],"that":[28,133],"metabotropic":[29],"glutamate":[30],"receptor":[31],"(mGluR)":[32],"ligands":[33,127],"are":[34],"neuroprotective":[35,123],"against":[36,130],"vitro.":[39],"In":[40],"present":[42],"study,":[43],"neurotoxin":[45],"6-hydroxydopamine":[46],"(6-OHDA)":[47],"produced":[48],"significant":[50],"loss":[51],"(61.2":[52],"+/-":[53,71],"8.9%;":[54],"P":[55,73],"<":[56,74],"0.01)":[57],"of":[58,125,140],"tyrosine":[59],"hydroxylase-immunopositive":[60],"(TH+)":[61],"cells":[62],"both":[64],"SNc":[66],"and":[67],"striatal":[68],"dopamine":[69],"(58.02":[70],"1.27%;":[72],"0.05)":[75],"control":[77],"male":[78],"Sprague-Dawley":[79],"rats.":[80],"Both":[81],"losses":[82],"were":[83],"significantly":[84],"attenuated":[85],"by":[86],"sub-chronic":[87],"(7":[88],"day)":[89],"treatment":[90,139],"with":[91],"Group":[93,104,112],"I":[94],"mGluR":[95,106,114,126],"antagonists,":[96],"2-methyl-6(phenylethynyl)-pyridine":[97],"(MPEP)":[98],"or":[99,110],"(S)-(+)-alpha-amino-4-carboxy-2-methylbenzeneacetic":[100],"acid":[101,117],"(LY367385);":[102],"II":[105],"agonist":[107],"(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate":[108],"(2R,4R-APDC);":[109],"III":[113],"agonist,":[115],"L(+)-2-amino-4-phosphonobutyric":[116],"(L-AP4).":[118],"These":[119],"data":[120],"demonstrate":[121],"action":[124],"vivo":[129],"6-OHDA":[131],"toxicity":[132],"has":[134],"important":[135],"implications":[136],"for":[137],"PD.":[141]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1964705113","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":9}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
